Mural Oncology Stock (NASDAQ:MURA)

Revenue Ownership Financials Chart

Previous Close

$3.65

52W Range

$2.88 - $6.25

50D Avg

$3.28

200D Avg

$3.87

Market Cap

$62.36M

Avg Vol (3M)

$94.73K

Beta

-

Div Yield

-

MURA Company Profile

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

107

IPO Date

Nov 16, 2023

Website

MURA Performance

MURA Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-194.64M	$-195.15M	$-175.37M
Net Income	$-207.45M	$-200.03M	$-175.43M
EBITDA	$-192.07M	$-193.61M	$-173.89M
Basic EPS	$-12.43	$-11.99	$-10.51
Diluted EPS	$-12.43	$-11.99	$-10.51

Fiscal year ends in Dec 23 | Currency in USD